Christina Barmpagianni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christina Barmpagianni has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Darius Rares Rad
Department of Paediatric Orthopaedics, University Hospital Southampton NHS Foundation Trust, Southampton, UK
2 shared publications - Emmanuel Spanoudakis
Department of Paediatric Orthopaedics, University Hospital Southampton NHS Foundation Trust, Southampton, UK
2 shared publications - Farokh Wadia
Department of Paediatric Orthopaedics, University Hospital Southampton NHS Foundation Trust, Southampton, UK
2 shared publications - Themistoklis Vampertzis
Department of Paediatric Orthopaedics, Royal National Orthopaedic Hospital, London, UK
2 shared publications - Athanasios Serlis
Department of Orthopaedics, Princess Alexandra Hospital NHS Trust, Harlow, UK
1 shared publication - Eleftherios Tsiridis
Academic Orthopaedic Department, Aristotle University Medical School, General Hospital Papageorgiou, Ring Road Efkarpia, 56403 Thessaloniki, Greece
1 shared publication
Latest Publications
- 22 June 2025
- Published by Springer Nature in European Journal of Orthopaedic Surgery & Traumatology
- Vol. 35 (1) , 1-8
Paediatric supracondylar humeral fractures: assessment and management
This paper aims to provide a structured approach to managing supracondylar humerus fractures in the paediatric population, informed by the most recent literature and guidelines. It aims to prepare candidates for the specialist examination in trauma and orthopaedic (e.g. Fellowship of the Royal College of Surgeons (FRCS), Fellowship of the European Board of Orthopaedics and Traumatology (FEBOT), Board Exams, etc.) while also emphasising important considerations for practitioners who may not frequently encounter paediatric supracondylar fractures.
- 22 June 2025
- Published by Springer Nature in European Journal of Orthopaedic Surgery & Traumatology
- Vol. 35 (1) , 1-8
Paediatric supracondylar humeral fractures: assessment and management
This paper aims to provide a structured approach to managing supracondylar humerus fractures in the paediatric population, informed by the most recent literature and guidelines. It aims to prepare candidates for the specialist examination in trauma and orthopaedic (e.g. Fellowship of the Royal College of Surgeons (FRCS), Fellowship of the European Board of Orthopaedics and Traumatology (FEBOT), Board Exams, etc.) while also emphasising important considerations for practitioners who may not frequently encounter paediatric supracondylar fractures.
- Open Access
- 4 June 2025
- Published by Springer Nature in European Journal of Orthopaedic Surgery & Traumatology
- Vol. 35 (1) , 1-10
Botulinum toxin in fracture management: a scoping review
Purpose: Using botulinum toxin (BoNT) as an adjunct in fracture management is a novel approach with the potential to improve clinical outcomes, particularly in atypical fractures and patients with concurrent neuromuscular disorders. This scoping review explores the literature on BoNT’s effectiveness in facilitating fracture healing and immobilisation across various fracture types. Methods: The PubMed, Embase, and Cochrane databases were searched with defined operators. Two investigators conducted independent searches, which were combined. Animal studies, case reports, case series, cohort reviews and randomised control trials were included. Results: Fifty studies were identified for screening, from which 15 studies were included in the review. The findings highlight mixed outcomes in BoNT’s role in enhancing bone healing and reducing muscle-induced displacement. While BoNT injections demonstrated potential benefits in specific cases, such as atypical fractures, periprosthetic fractures and fractures in patients with motor dysfunctions, results from animal studies were inconsistent, showing varied effects on callous formation and bone mineral density. Conclusion: Clinical applications of BoNT in fracture management indicate its utility as an immobilisation agent to promote fracture healing and reduce complications. However, this review highlights that further research is necessary to bridge the gap between experimental and clinical studies and to clarify BoNT’s effectiveness in different use cases.
- 4 June 2025
- Published by Springer Nature in European Journal of Orthopaedic Surgery & Traumatology
- Vol. 35 (1) , 1-10
Open AccessBotulinum toxin in fracture management: a scoping review
Purpose: Using botulinum toxin (BoNT) as an adjunct in fracture management is a novel approach with the potential to improve clinical outcomes, particularly in atypical fractures and patients with concurrent neuromuscular disorders. This scoping review explores the literature on BoNT’s effectiveness in facilitating fracture healing and immobilisation across various fracture types. Methods: The PubMed, Embase, and Cochrane databases were searched with defined operators. Two investigators conducted independent searches, which were combined. Animal studies, case reports, case series, cohort reviews and randomised control trials were included. Results: Fifty studies were identified for screening, from which 15 studies were included in the review. The findings highlight mixed outcomes in BoNT’s role in enhancing bone healing and reducing muscle-induced displacement. While BoNT injections demonstrated potential benefits in specific cases, such as atypical fractures, periprosthetic fractures and fractures in patients with motor dysfunctions, results from animal studies were inconsistent, showing varied effects on callous formation and bone mineral density. Conclusion: Clinical applications of BoNT in fracture management indicate its utility as an immobilisation agent to promote fracture healing and reduce complications. However, this review highlights that further research is necessary to bridge the gap between experimental and clinical studies and to clarify BoNT’s effectiveness in different use cases.